AGC Pharma Chemicals Appoints Jun Kurihara as CEO

• Jun Kurihara has been appointed CEO of AGC Pharma Chemicals, effective 1 June 2025.

• Kurihara succeeds Akihiro Kadokura, who will become Senior Executive Advisor at AGC Life Science.

AGC Pharma Chemicals, a contract development and manufacturing organisation (CDMO), has announced the appointment of Jun Kurihara as its new Chief Executive Officer, effective 1 June 2025. Kurihara currently serves as Executive Vice President and has held leadership roles within the company and at AstraZeneca.

Kurihara brings over nine years of experience in the pharmaceutical industry and has led strategic projects that helped AGC Pharma Chemicals reach near-maximum operational capacity. His expertise spans business development, marketing, and operations, positioning him to guide the company through its next growth phase in the CDMO sector.

“I am deeply honored by the opportunity to lead AGC Pharma Chemicals in this new phase,” said Jun Kurihara. “My goal is to strengthen the company’s position as a leading strategic partner in the CDMO sector, driving operational excellence, innovation, quality, and sustainable growth.”

The leadership transition follows the tenure of Akihiro Kadokura, who will assume the role of Senior Executive Advisor at AGC Life Science. During his time as CEO, Kadokura advanced the company’s presence in Europe and contributed to its strategic project portfolio and culture of collaboration.